Cargando…

Secondary hyperparathyroidism, weight loss, and longer term mortality in haemodialysis patients: results from the DOPPS

BACKGROUND: Wasting is a common complication of kidney failure that leads to weight loss and poor outcomes. Recent experimental data identified parathyroid hormone (PTH) as a driver of adipose tissue browning and wasting, but little is known about the relations among secondary hyperparathyroidism, w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Komaba, Hirotaka, Zhao, Junhui, Yamamoto, Suguru, Nomura, Takanobu, Fuller, Douglas S., McCullough, Keith P., Evenepoel, Pieter, Christensson, Anders, Zhao, Xinju, Alrukhaimi, Mona, Al‐Ali, Fadwa, Young, Eric W., Robinson, Bruce M., Fukagawa, Masafumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350219/ https://www.ncbi.nlm.nih.gov/pubmed/34060245 http://dx.doi.org/10.1002/jcsm.12722

Ejemplares similares

Mineral and bone disorder management in hemodialysis patients: comparing PTH control practices in Japan with Europe and North America: the Dialysis Outcomes and Practice Patterns Study (DOPPS)
por: Yamamoto, Suguru, et al.
Publicado: (2018)

Impact of longer term phosphorus control on cardiovascular mortality in hemodialysis patients using an area under the curve approach: results from the DOPPS
por: Lopes, Marcelo Barreto, et al.
Publicado: (2020)

Association between long-term efficacy of cinacalcet and parathyroid gland volume in haemodialysis patients with secondary hyperparathyroidism
por: Tanaka, Motoko, et al.
Publicado: (2008)

Fibroblast Growth Factor 23 and Mortality Among Prevalent Hemodialysis Patients in the Japan Dialysis Outcomes and Practice Patterns Study
por: Komaba, Hirotaka, et al.
Publicado: (2020)

Thrombocytopenia predicts mortality in Chinese hemodialysis patients- an analysis of the China DOPPS
por: Zhao, Xinju, et al.
Publicado: (2022)

Serum total indoxyl sulfate and clinical outcomes in hemodialysis patients: results from the Japan Dialysis Outcomes and Practice Patterns Study
por: Yamamoto, Suguru, et al.
Publicado: (2020)

Baseline data report of the China Dialysis Outcomes and Practice Patterns Study (DOPPS)
por: Zhao, Xinju, et al.
Publicado: (2021)

The risk of medically uncontrolled secondary hyperparathyroidism depends on parathyroid hormone levels at haemodialysis initiation
por: Tabibzadeh, Nahid, et al.
Publicado: (2020)

Japanese haemodialysis anaemia management practices and outcomes (1999–2006): results from the DOPPS
por: Akizawa, Tadao, et al.
Publicado: (2008)

The whole-PTH/intact-PTH ratio is a useful predictor of severity of secondary hyperparathyroidism
por: Tanaka, Motoko, et al.
Publicado: (2008)

Response to Letter to the Editor From Sumi et al: “Lower Bone Turnover and Skeletal PTH Responsiveness in Japanese Compared to European Patients Receiving Hemodialysis”
por: Jørgensen, Hanne Skou, et al.
Publicado: (2022)

Understanding associations of hemodialysis practices with clinical and patient-reported outcomes: examples from the DOPPS
por: Port, Friedrich K., et al.
Publicado: (2017)

Pathophysiology of parathyroid hyperplasia in chronic kidney disease: preclinical and clinical basis for parathyroid intervention
por: Goto, Shunsuke, et al.
Publicado: (2008)

Relapse of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine
por: Komaba, Hirotaka, et al.
Publicado: (2021)

The association between longer haemodialysis treatment times and hospitalization and mortality after the two-day break in individuals receiving three times a week haemodialysis
por: Fotheringham, James, et al.
Publicado: (2019)

Phase 2 study of upacicalcet in Japanese haemodialysis patients with secondary hyperparathyroidism: an intraindividual dose-adjustment study
por: Inaguma, Daijo, et al.
Publicado: (2023)

Optimizing the cost-effectiveness of treatment for chronic kidney disease-mineral and bone disorder
por: Goto, Shunsuke, et al.
Publicado: (2013)

Effectiveness of cinacalcet treatment for secondary hyperparathyroidism on hospitalization: Results from the MBD-5D study
por: Asada, Shinji, et al.
Publicado: (2019)

Interleukin-6 receptor inhibition with tocilizumab in various renal involvements associated with multicentric Castleman's disease: a report of three cases
por: Komaba, Hirotaka, et al.
Publicado: (2008)

A Retrospective Study on Erythropoiesis Stimulating Agent Dose Reducing Potential of an Anti‐Platelet Activation Membrane Dialyzer in Hemodialysis Patients
por: Kakuta, Takatoshi, et al.
Publicado: (2018)

Acute cardiac overload does not induce cardiac or skeletal expression of fibroblast growth factor 23 in rats
por: Fajol, Abul, et al.
Publicado: (2021)

High facility-level serum potassium variability associated with mortality in hemodialysis patients: results from Chinese Dialysis Outcomes and Practice Patterns Study (DOPPS)
por: Zhao, Xinju, et al.
Publicado: (2023)

Control of severe hyperparathyroidism in dialysis patients with nodular hyperplasia
por: Fukagawa, Masafumi, et al.
Publicado: (2008)

Evaluating the effectiveness of IV iron dosing for anemia management in common clinical practice: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS)
por: Robinson, Bruce M., et al.
Publicado: (2017)

The Pituitary Is a Candidate Organ That Modulates Circulating Klotho Levels
por: Sato, Tetsuhiko, et al.
Publicado: (2018)

Changes in 3-month mineral and bone disorder patterns were associated with all-cause mortality in prevalent hemodialysis patients with secondary hyperparathyroidism
por: Kato, Chihiro, et al.
Publicado: (2020)

Hemoglobin A(1c) Levels and Mortality in the Diabetic Hemodialysis Population: Findings from the Dialysis Outcomes and Practice Patterns Study (DOPPS)
por: Ramirez, Sylvia Paz B., et al.
Publicado: (2012)

Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients
por: Shigematsu, Takashi, et al.
Publicado: (2018)

Multicentre, observational, retrospective cohort of hyperkalaemia burden at haemodialysis facility-level in China: the Visualize-HD study protocol
por: Zhao, Xinju, et al.
Publicado: (2023)

Reversed whole PTH/intact PTH ratio as an indicator of marked parathyroid enlargement: five case studies and a literature review
por: Komaba, Hirotaka, et al.
Publicado: (2008)

Potential life-years gained over a 5-year period by correcting DOPPS-identified modifiable practices in haemodialysis: results from the European MONITOR-CKD5 study
por: Combe, Christian, et al.
Publicado: (2019)

Haemoglobin concentration and survival of haemodialysis patients before and after experiencing cardiovascular disease: a cohort study from Japanese dialysis outcomes and practice pattern study (J-DOPPS)
por: Kido, Ryo, et al.
Publicado: (2019)

A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients
por: Fukagawa, Masafumi, et al.
Publicado: (2017)

Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism
por: Akizawa, Tadao, et al.
Publicado: (2019)

Long-Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis
por: Yokoyama, Keitaro, et al.
Publicado: (2019)

Efficacy of Evocalcet in Previously Cinacalcet-Treated Secondary Hyperparathyroidism Patients
por: Koiwa, Fumihiko, et al.
Publicado: (2021)

Evocalcet with vitamin D receptor activator treatment for secondary hyperparathyroidism
por: Shigematsu, Takashi, et al.
Publicado: (2022)

Facility Variation and Predictors of Do Not Resuscitate Orders of Hemodialysis Patients in Canada: DOPPS
por: Moorman, Danielle, et al.
Publicado: (2019)

Pharmacokinetics of evocalcet in secondary hyperparathyroidism patients receiving hemodialysis: first-in-patient clinical trial in Japan
por: Shigematsu, Takashi, et al.
Publicado: (2018)

Discrepancies between bioimpedance spectroscopy devices in haemodialysis patients
por: Dejongh, Sander, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kdlkuftjktjm80fkmilfadqjgc